ǰɻ(ɻ, ) 2014 7~12(6) ǽ 1 1 7 Ȩ Ͽ. Ȩ(www.hira.or.kr) Ͽ <> – <> ϸ ִ.
츮 ֿ ̸, Ư ߺ 1 μ 2013 Ƿ ū Ÿ ҽŰ, ܰ Ȯ ̷ Ǵ ġḦ ǽϰ ִ Ű ǽϿ. 1~4 еǸ, ̹ 1Ⱑ 74.5% 3(12.2%), 2(10.4%), 4(2.9%) ̾. 1 TNM з 캸, Ǵ ϰ ̴ T1N0 ° 67.5% Ͽ ߰ߵǴ Ÿ. ɺδ (68.7%) (31.3%) 2 ̻ Ÿ Ư, 60(31.7%), 70(24.1%)밡 Ÿ. 90 ̻ Ǵ 20뿡 ſ Ͽ.
Ͽ ϼ(ð, ) 201 9,969 ǽϿ. պ 52, պ 42, 1Ҹ Ͽ. ü 95.30 . պ(97.52) (94.50), պ(93.51) ̴.
, ǥ ġ 5 η θ Ȯϴ ü 81.7% ټ Ÿ. 5 ܰ, ȭ⳻, 系, , а شȴ. ϴ ǥ (3 ǥ), (6 ǥ), ȭп (6 ǥ) 94.4%~99.9% . Ư, ġ Ŀ ߿ Ǵܱ Ǵ ˻ ü 98.2%̸, ġ ֵ ǰϴ Ͽ ġ 98.1% ϰ ̷ ִ Ÿ. ٸ, ð 鿡 ϼ ϴ ɼ ּȭϱ ߰ ǰϴ ð ߰ ǽ ü 76.3%̸, պ 77.8%, պ 73.3% Ÿ. ƿ, ñ Ͽ ߹ ֵ ǰϰ ִ 8 ̳ ǰ ȭп ǽ(23) ü 84.0%, պ 86.2%, պ 80.7%, 77.8% Ư Ÿ ̸ ϱ ʿ Ǵܵȴ.
ǥ ȯڿ ϰ ̷ ϱ ü 0.88% ȯڸ 캻 , ̷ ¿ ϴ , Ⱑ 4 , ȯ ° (ASA score 3 ̻), 75 ̻ Ÿ. ߿ ǰ ȭп S1(tegafur + gimeracil + oteracil) XELOX(capecitabine + oxaliplatin) Ѵ. Ϻ 4 ̰ ִ ̸, 1~3 ̰ · ħ, еȴ. ASA ǻ簡 ȯڻ¸ Ͽ οϴ Ѵ.
ǥ 5 Ͽ Ͽ, 201 9,969 ؿ شϴ 95 (ü 47.3%) 9,597(ü 96.3%) Ͽ. Ǽ 6 ̻(ð )̸鼭 ȭп õ Ϸ, 8̳ ǰ ȭп , ǰ ȭп ǽ, 뿡 ǽ 6 ǥ ּ 3 ̻ μ ϰ Ͽ. 95 1 85 (89.5%) (26) Ұ (21), (17) ڸ ̾. 2 5, 3 2̴.
, Ű ٽ ǥ ȭп Ÿ. ̹ 1 ȣ ̴ 2012 ǽ ߿伺 ϰ, ħ ؿ Ǵܵȴ.
ɻ 1 ε Ƿ ϴµ ֵ Ƿ , ǥ Ȩ ϰ, 2016 1 ȸ ֿ Ҿ ؼ 湮 Ȱ ȹ̴.
* TN з
з> з>
∙ T1: ∙ N0: lymph node (-)
∙ T2: ∙ N1: 1~2 positive lymph node
∙ T3: 帷 ∙ N2: 3~6 positive lymph node
∙ T4: 帷 Ǵ ħ∙ N3: 7 or more positive lymph node